Tumor necrosis factors blocking agents: analogies and differences

Tumor necrosis factors blocking agents: analogies and differences

Authors

  • M. Benucci
  • G. Saviola
  • M. Manfredi, et al.

Keywords:

anti-TNF agents, pharmacokinetic, tumor necrosis factor

Abstract

Five anti-TNF agents, infliximab, adalimumab, etanercept, golimumab and certolizumab pegol are approved worldwide for the treatment of RA. Anti-TNF agents, bind to and neutralize soluble TNF-α, but exert different effects on transmembrane TNF-α-expressing cells (TNF-α-producing cells). Differences on affinity and avidity for soluble and transmembrane TNF-α were showed. Different activity on cells apoptosis, Complement-dependent cytotoxicity (CDC) antibody dependent cell-mediated cytotoxicity (ACDC) were described. Some dramatic changes in gene expression were seen with all the anti-TNFs. Reviewing the biology of transmembrane TNF-α and its interaction with anti-TNF agents will contribute to understanding the bases of differential clinical efficacy of these promising treatment modalities.

Downloads

Published

01-06-2012

Issue

Section

Up to date

How to Cite

1.
Tumor necrosis factors blocking agents: analogies and differences. Acta Biomed [Internet]. 2012 Jun. 1 [cited 2024 Mar. 29];83(1):72-80. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/2064